British American Tobacco: The Market Underestimates How Big Velo Can Become

British American Tobacco received a Buy rating at approximately $53, supported by Velo's rapid growth and strong Modern Oral market shares in the US and Europe. The analyst cites New Categories margin expansion and cost savings as drivers of projected 5–8% EPS growth and attractive total returns.

Analysis

The key question is whether Velo is expanding the profit pool or mainly shifting existing nicotine users between formats. Share gains alone would overstate the investment case if category growth slows, repeat use weakens, or pouch sales displace higher-contribution products faster than New Categories margins improve. The next 1–3 months are about verifying the quality of growth in reported category volume, market share, and segment profitability—not extrapolating analyst EPS expectations. Over 6–18 months, durable growth depends on regulatory access and continued conversion to modern oral products; tighter product or marketing rules could cap both distribution and brand investment. Philip Morris International and other nicotine-product competitors may respond with promotions, raising the cost of defending share. The contrarian risk is that a favorable product narrative masks combustible declines or growth that requires uneconomic spending. No supplied evidence establishes that Velo’s growth has yet translated into consolidated earnings at the expected pace.

Key Decisions for Investors

• Treat BTI as a conditional, medium-term long rather than a momentum chase: consider staged entry after the next results confirm that New Categories margin improvement accompanies volume and share gains.
• Before adding, verify category-level sales growth, repeat-purchase or consumption indicators where disclosed, segment margins, and the effect of New Categories on consolidated earnings; share leadership by itself is insufficient.
• Falsify the thesis if subsequent disclosures show slowing pouch growth, share losses, margin deterioration, or guidance that fails to support the expected EPS trajectory. Reassess as well if regulatory action materially restricts product authorization, marketing, or distribution.
• If those confirming data are unavailable or the shares have already moved on the analyst narrative, remain on watch rather than forcing a trade; the central risk is paying for growth before its earnings contribution is demonstrated.